Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human bone marrow mesenchymal stem cell injection
- Development stage
- Phase 2
- Lead developer
- Jiuzhitang Meike
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human bone marrow mesenchymal stem cell injection is an allogeneic cell therapy product developed by Jiuzhitang Meike (Beijing) Cell Technology, utilizing ischemia-tolerant mesenchymal stem cell (it-MSC) technology licensed from Stemedica Cell Technologies. The product consists of mesenchymal stem cells derived from the bone marrow of healthy adult donors, which are expanded under low-oxygen (hypoxic) conditions to enhance their survival, migration, and therapeutic potency upon transplantation. These cells possess potent immunomodulatory and anti-inflammatory properties, acting through the secretion of various cytokines and growth factors that modulate the activity of T cells, B cells, and macrophages. In the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), the injection is intended to address underlying immune dysfunction and potentially improve the clearance of surfactant by restoring alveolar macrophage function. The therapy is currently being evaluated in Phase II clinical trials for aPAP and ischemic stroke in China.
- Other names
- hBMMSChBMMSC injection人骨髓间充质干细胞注射液
Beyond the preview
Go deeper on human bone marrow mesenchymal stem cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human bone marrow mesenchymal stem cell injection.